Dimensional Fund Advisors LP Invests $587,000 in Ultragenyx Pharmaceutical Inc (RARE)

Dimensional Fund Advisors LP purchased a new stake in shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) in the second quarter, Holdings Channel reports. The firm purchased 7,635 shares of the biopharmaceutical company’s stock, valued at approximately $587,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Swiss National Bank grew its position in shares of Ultragenyx Pharmaceutical by 5.7% during the 2nd quarter. Swiss National Bank now owns 82,052 shares of the biopharmaceutical company’s stock valued at $6,307,000 after purchasing an additional 4,400 shares in the last quarter. Amalgamated Bank grew its position in shares of Ultragenyx Pharmaceutical by 20.8% during the 2nd quarter. Amalgamated Bank now owns 7,176 shares of the biopharmaceutical company’s stock valued at $552,000 after purchasing an additional 1,236 shares in the last quarter. American Century Companies Inc. grew its position in shares of Ultragenyx Pharmaceutical by 52.4% during the 2nd quarter. American Century Companies Inc. now owns 55,975 shares of the biopharmaceutical company’s stock valued at $4,303,000 after purchasing an additional 19,255 shares in the last quarter. Strs Ohio grew its position in shares of Ultragenyx Pharmaceutical by 358.3% during the 2nd quarter. Strs Ohio now owns 5,500 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 4,300 shares in the last quarter. Finally, UBS Group AG grew its position in shares of Ultragenyx Pharmaceutical by 378.5% during the 1st quarter. UBS Group AG now owns 114,152 shares of the biopharmaceutical company’s stock valued at $5,821,000 after purchasing an additional 90,294 shares in the last quarter. Hedge funds and other institutional investors own 96.12% of the company’s stock.

NASDAQ RARE opened at $49.43 on Wednesday. Ultragenyx Pharmaceutical Inc has a 52-week low of $41.67 and a 52-week high of $90.98. The firm has a market cap of $2.44 billion, a PE ratio of -6.59 and a beta of 1.95.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. The company had revenue of $12.79 million during the quarter, compared to the consensus estimate of $5.63 million. During the same period in the previous year, the firm posted ($1.72) EPS. On average, research analysts predict that Ultragenyx Pharmaceutical Inc will post -4.38 earnings per share for the current fiscal year.

A number of research firms have recently commented on RARE. Credit Suisse Group reduced their price target on shares of Ultragenyx Pharmaceutical from $78.00 to $59.00 and set a “hold” rating for the company in a research report on Monday. Wedbush boosted their price target on shares of Ultragenyx Pharmaceutical from $71.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, August 6th. JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 29th. Raymond James set a $70.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Friday, October 26th. Finally, Citigroup reduced their price target on shares of Ultragenyx Pharmaceutical from $49.00 to $46.00 and set a “sell” rating for the company in a research report on Monday. Two analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the stock. Ultragenyx Pharmaceutical currently has a consensus rating of “Buy” and a consensus price target of $77.00.

In other news, Director William Aliski sold 19,550 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, October 8th. The shares were sold at an average price of $72.49, for a total transaction of $1,417,179.50. Following the completion of the sale, the director now directly owns 72,610 shares of the company’s stock, valued at approximately $5,263,498.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Shalini Sharp sold 6,700 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total transaction of $603,469.00. Following the sale, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at $5,118,497.96. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock valued at $2,700,774 over the last ninety days. 8.40% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Recommended Story: Intrinsic Value

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply